The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Journal
NPJ breast cancer
Journal Volume
7
Journal Issue
1
Date Issued
2021-12-01
Author(s)
El Bairi, Khalid
Haynes, Harry R
Blackley, Elizabeth
Fineberg, Susan
Shear, Jeffrey
Turner, Sophia
de Freitas, Juliana Ribeiro
Sur, Daniel
Amendola, Luis Claudio
Gharib, Masoumeh
Kallala, Amine
Arun, Indu
Azmoudeh-Ardalan, Farid
Fujimoto, Luciana
Sua, Luz F
Liu, Shi-Wei
Kirtani, Pawan
Balancin, Marcelo
El Attar, Hicham
Guleria, Prerna
Yang, Wenxian
Shash, Emad
Bautista, Veronica
Do Prado Moura, Jose Fernando
Rapoport, Bernardo L
Castaneda, Carlos
Spengler, Eunice
Acosta-Haab, Gabriela
Frahm, Isabel
Sanchez, Joselyn
Castillo, Miluska
Bouchmaa, Najat
Md Zin, Reena R
Shui, Ruohong
Onyuma, Timothy
Yang, Wentao
Husain, Zaheed
Willard-Gallo, Karen
Coosemans, An
Perez, Edith A
Provenzano, Elena
Ericsson, Paula Gonzalez
Richardet, Eduardo
Mehrotra, Ravi
Sarancone, Sandra
Ehinger, Anna
Rimm, David L
Bartlett, John M S
Viale, Giuseppe
Denkert, Carsten
Hida, Akira I
Sotiriou, Christos
Loibl, Sibylle
Hewitt, Stephen M
Badve, Sunil
Symmans, William Fraser
Kim, Rim S
Pruneri, Giancarlo
Goel, Shom
Francis, Prudence A
Inurrigarro, Gloria
Yamaguchi, Rin
Garcia-Rivello, Hernan
Horlings, Hugo
Afqir, Said
Salgado, Roberto
Adams, Sylvia
Kok, Marleen
Dieci, Maria Vittoria
Michiels, Stefan
Demaria, Sandra
Loi, Sherene
Abstract
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
Subjects
TUMOR-INFILTRATING LYMPHOCYTES; NEOADJUVANT CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; PREDICTIVE-VALUE; FREE SURVIVAL; TRASTUZUMAB; SUBTYPES; MICROENVIRONMENT; IDENTIFICATION; ASSOCIATION
SDGs
Other Subjects
atezolizumab; cisplatin; cyclophosphamide; doxorubicin; durvalumab; epirubicin; lapatinib; letrozole; nivolumab; pembrolizumab; programmed death 1 ligand 1; programmed death 1 receptor; tamoxifen; trastuzumab; breast cancer; circulating tumor cell; cost effectiveness analysis; human; lymphocytic infiltration; middle income country; Review; triple negative breast cancer; tumor associated leukocyte
Publisher
NATURE PORTFOLIO
Type
review